Mariana Oncology’s CEO talks about radiopharmaceuticals and last week’s $175M Series B financing
Brent Saunders talks about his priorities for growth at Bausch + Lomb
Caribou Biosciences’ CEO on working toward a pivotal trial in 2nd line LBCL
Arcellx’s CMO gives an update on their BCMA program at the 2023 CAR-TCR Summit
Cellares’ CEO on building out the Cell Shuttle to automate cell therapy manufacturing
BlueRock’s CEO on the Parkinson’s cell therapy data that was presented today at #MDSCongress
Fulcrum Therapeutics’ CEO discusses the clinical hold lift of the company’s SCD program.
Catching up with the co-founders of Amylyx on the launch of their ALS treatment
Focusing on mitochondrial dysfunction to treat disease with Stealth BioTherapeutics’ CEO
Alltrna raises $109 million in a Series B financing to advance tRNA based therapies
Tracking recent β-thal and CALD gene therapy launches with bluebird’s CEO
Enanta’s CEO discusses RSV and Covid drug development on its earnings day
How a new CEO has been trying to position Editas to execute on the promise of CRISPR
Exclusive: Pfizer’s CEO on Q2 earnings
Immunogen’s CEO comments on Q2 earnings
Nanobiotix's CEO explains how his company is trying to boost the efficacy of radiation therapy
Trying to sell a diabetes drug (SGLT2 inhibitor) for around $1.50 a pill vs the $20 industry norm
Pioneering Medicines' Paul Biondi on today’s deal with Pfizer
Eleven Therapeutics on trying to help Novo Nordisk find the next GalNAc
Korro Bio CEO on RNA editing and the process behind reverse mergers
.png){kind=logo}
